vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and SUTRO BIOPHARMA, INC. (STRO). Click either name above to swap in a different company.

CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $11.6M, roughly 1.6× SUTRO BIOPHARMA, INC.). On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs -21.4%). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs -5.4%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...

CURI vs STRO — Head-to-Head

Bigger by revenue
CURI
CURI
1.6× larger
CURI
$19.2M
$11.6M
STRO
Growing faster (revenue YoY)
CURI
CURI
+57.2% gap
CURI
35.8%
-21.4%
STRO
Faster 2-yr revenue CAGR
CURI
CURI
Annualised
CURI
26.5%
-5.4%
STRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
STRO
STRO
Revenue
$19.2M
$11.6M
Net Profit
$-3.8M
Gross Margin
Operating Margin
-17.6%
Net Margin
-19.7%
Revenue YoY
35.8%
-21.4%
Net Profit YoY
-34.6%
35.4%
EPS (diluted)
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
STRO
STRO
Q4 25
$19.2M
$11.6M
Q3 25
$18.4M
$9.7M
Q2 25
$19.0M
$63.7M
Q1 25
$15.1M
$17.4M
Q4 24
$14.1M
$14.8M
Q3 24
$12.6M
$8.5M
Q2 24
$12.4M
$25.7M
Q1 24
$12.0M
$13.0M
Net Profit
CURI
CURI
STRO
STRO
Q4 25
$-3.8M
Q3 25
$-3.7M
$-56.9M
Q2 25
$784.0K
$-11.5M
Q1 25
$319.0K
$-76.0M
Q4 24
$-2.8M
$-72.4M
Q3 24
$-3.1M
$-48.8M
Q2 24
$-2.0M
$-48.0M
Q1 24
$-5.0M
$-58.2M
Operating Margin
CURI
CURI
STRO
STRO
Q4 25
-17.6%
Q3 25
-24.5%
-499.9%
Q2 25
2.5%
-5.2%
Q1 25
0.5%
-393.8%
Q4 24
-27.4%
-440.7%
Q3 24
-25.8%
-797.2%
Q2 24
-20.6%
-189.4%
Q1 24
-30.4%
-435.0%
Net Margin
CURI
CURI
STRO
STRO
Q4 25
-19.7%
Q3 25
-20.4%
-586.6%
Q2 25
4.1%
-18.0%
Q1 25
2.1%
-436.6%
Q4 24
-19.9%
-489.2%
Q3 24
-24.3%
-572.6%
Q2 24
-16.4%
-186.8%
Q1 24
-42.0%
-447.5%
EPS (diluted)
CURI
CURI
STRO
STRO
Q4 25
$-0.07
Q3 25
$-0.06
$-0.67
Q2 25
$0.01
$-0.14
Q1 25
$0.01
$-0.91
Q4 24
$-0.05
$-27.63
Q3 24
$-0.06
$-0.59
Q2 24
$-0.04
$-0.59
Q1 24
$-0.09
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
STRO
STRO
Cash + ST InvestmentsLiquidity on hand
$27.3M
$141.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$-132.5M
Total Assets
$75.7M
$173.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
STRO
STRO
Q4 25
$27.3M
$141.4M
Q3 25
$27.8M
$167.6M
Q2 25
$28.1M
$205.1M
Q1 25
$33.4M
$249.0M
Q4 24
$32.1M
$316.9M
Q3 24
$33.2M
$388.3M
Q2 24
$39.5M
$375.6M
Q1 24
$38.8M
$267.6M
Stockholders' Equity
CURI
CURI
STRO
STRO
Q4 25
$41.5M
$-132.5M
Q3 25
$47.2M
$-87.3M
Q2 25
$49.8M
$-32.1M
Q1 25
$58.1M
$-25.8M
Q4 24
$57.8M
$44.6M
Q3 24
$62.2M
$111.2M
Q2 24
$64.8M
$152.2M
Q1 24
$67.0M
$98.0M
Total Assets
CURI
CURI
STRO
STRO
Q4 25
$75.7M
$173.8M
Q3 25
$74.7M
$209.7M
Q2 25
$78.7M
$262.4M
Q1 25
$85.3M
$321.4M
Q4 24
$86.2M
$387.2M
Q3 24
$87.6M
$451.8M
Q2 24
$90.9M
$489.0M
Q1 24
$94.6M
$403.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
STRO
STRO
Operating Cash FlowLast quarter
$4.0M
$-177.2M
Free Cash FlowOCF − Capex
$3.9M
FCF MarginFCF / Revenue
20.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
STRO
STRO
Q4 25
$4.0M
$-177.2M
Q3 25
$4.4M
$-38.2M
Q2 25
$2.8M
$-44.7M
Q1 25
$1.9M
$-67.9M
Q4 24
$3.0M
$-71.7M
Q3 24
$2.3M
$-64.5M
Q2 24
$2.2M
$9.5M
Q1 24
$666.0K
$-64.7M
Free Cash Flow
CURI
CURI
STRO
STRO
Q4 25
$3.9M
Q3 25
Q2 25
Q1 25
$1.8M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
CURI
CURI
STRO
STRO
Q4 25
20.5%
Q3 25
Q2 25
Q1 25
12.2%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
CURI
CURI
STRO
STRO
Q4 25
0.1%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CURI
CURI
STRO
STRO
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons